Aclidinium bromide dose-ranging trial versus placebo and formoterol in moderate to severe COPD

Phase 2 trial of aclidinium in chronic obstructive pulmonary disease (COPD) (5 arms), sponsored by Almirall. Primary endpoint: Change from baseline in normalised FEV1 area under the curve over the 12-hour period. Started Jan 2010; status: completed.